Lucid Diagnostics Inc. (LUCD): Forward P/S Multiple

Slow adoption rates for EsoGuard insurance and marketing expenses are weighing on Lucid Diagnostics Inc. (LUCD) capital. However, the optimization of distribution centers is improving profitability, and the P/S expectations for the company provided by the GURU.Markets system confirm this trend, where 14.60 expresses the latest metric level. Efficient express delivery of biomaterials to laboratories accelerates oncology diagnoses, ensuring the accuracy of results.

luciddx.com - LUCD Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Lucid Diagnostics, Inc (LUCD)

- stock price and consensus target price:

Stock Quotes Lucid Diagnostics|LUCD - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Capitalization Lucid Diagnostics, Inc|LUCD - Real Price to Acquire Entire Company

- issuer book value statistics:

Book Value per Share Lucid Diagnostics|LUCD - Book Valuation of Business|Market Capitalization to Book Value Ratio luciddx.com|LUCD - Total Business Assets

- debt level and financial liquidity data:

- financial results and valuation multiples details:

LUCD - Annual Net Income|Expected Profit Lucid Diagnostics Inc.|LUCD - Price to Earnings Multiple|Future Price to Earnings Lucid Diagnostics Inc|LUCD - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lucid Diagnostics, Inc|LUCD - Operating income before deduction of amortization|Net earnings per share for the last 12 months Lucid Diagnostics|LUCD - Earnings per share for the last four quarters|Quarterly EPS earnings growth luciddx.com|LUCD - Expected net earnings per share growth this year|Earnings growth forecast for next year Lucid Diagnostics Inc.

- sales volume and revenue indicators:

LUCD - Company Sales|Company Projected Revenue Lucid Diagnostics|LUCD - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Lucid Diagnostics, Inc

Fundamental company valuation:Lucid Diagnostics LUCD

Manufactured products of Lucid Diagnostics, Inc

This ratio determines the market value of a business relative to expected future sales, allowing an investor to assess the premium paid per unit of future revenue. By analyzing the forward P/S multiple on the GURU.Markets platform, one can confirm the resilience of Lucid Diagnostics Inc. (LUCD), as the defensive nature of esophageal cancer diagnostics minimizes valuation volatility risks during economic downturns.

Analysis of competing companies

Agilent - Forward Price-to-Revenue Multiple|Forward P/S Multiple Quest Diagnostics Inc. DGX|Illumina Corp - Forward P/S Multiple|Exact Sciences Inc. (EXAS) - Forward Price-to-Revenue Multiple|RVTY: Forward P/S Multiple|BIO - Market Cap to Expected Sales Ratio|NNNN (Anbio) - Forward P/S Multiple|Market Cap to Projected Revenue SHC (Sotera Health Corp)|Forward Price-to-Revenue Multiple QDEL (QuidelOrtho Corp)|OPK (OPKO Health Corp.) - Forward Price to Sales|Forward P/S Multiple CDNA (CareDx, Inc)|MRVI: Market Cap to Projected Revenue|Fulgent Genetics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Standard BioTools Inc LAB|CTKB: Forward P/S Multiple|OraSure Corp (OSUR) - Forward P/S Multiple|XGN (Exagen Inc) - Forward P/S Multiple|MDXH - Projected Price to Revenue|Price-to-Projected Revenue Ratio Prenetics Global (PRE)|imdxinc.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Trinity Biotech TRIB|ProPhase Labs Corp (PRPH) - Market Cap to Future Revenue Ratio|AIMD - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio codiagnostics.com CODX|HSCS (HeartSciences) - Forward Price-to-Revenue Multiple|BMRA: Price to Expected Revenue Ratio|CDIO (Cardio Diagnostics Holdings Inc.) - Forward P/S Multiple|Onconetix Corporation (ONCO) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VRAX|Forward Price-to-Revenue Multiple bluejaydx.com BJDX|Price-to-Projected Revenue Ratio Aspira Women's Health Inc. AWH|Market Cap to Expected Sales Ratio Accelerate Diagnostics Inc. (AXDX)|CNTG: Forward Price-to-Revenue Multiple|Forward Price to Sales ENZ (Enzo Biochem, Inc.)|FRES: Forward P/S Multiple|GENE - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio 23andMe|Market Cap to Projected Revenue PMD (Psychemedics Corp.)